Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Participants who complete the study will have the option to enter the long-term extension Study I6T-MC-AMAZ (AMAZ).
Age
2–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females weighing ≥10 kg and ≥2 and \<18 years old at the time of consent for screening.
Have moderate to severe UC.
Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.
Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.
You may not be if
Have Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis or primary sclerosing cholangitis.
Have immune deficiency syndrome.
Previous bowel resection or intestinal surgery.
Evidence of toxic megacolon.
History or current evidence of cancer of the gastrointestinal tract.
Clareo Health | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
